S. Marchetti

Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.

A. Santoro, L. Giordano, A. Marrari, 2015, Anticancer research.

Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?

A. Santoro, S. Rossi, L. Toschi, 2018, Immunotherapy.

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma

C. Mussi, A. Santoro, A. Marrari, 2015, Drug design, development and therapy.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Nina Tunariu, Andrea Lampis, Mihaela Rata, 2017, Gut.

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery

P. Allavena, M. Alloisio, A. Santoro, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma

A. Marrari, R. Sanctis, A. Bertuzzi, 2015 .

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma

A. Marrari, R. Sanctis, A. Bertuzzi, 2015 .